Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 1 Hodgkin Disease 1 Castrate Resistant Prostate Cancer 1

Interventions

Dexamethasone 8 daratumumab 5 Lenalidomide 5 Bortezomib 5 Thalidomide 4 Cyclophosphamide 4 carfilzomib 2 Melphalan 2 Calcium Dobesilate 2 trametinib 1 tanespimycin 1 pomalidomide 1 fludarabine 1 dabrafenib 1 cobimetinib 1 Whole-Body Irradiation 1 Vemurafenib 1 Stem Cell Transplantation 1 Rivaroxaban 1 Mesna 1 MAGEA3 protein, human 1 Lenograstim 1 Human Growth Hormone 1 Hematopoietic Stem Cell Transplantation 1 Granulocyte Colony-Stimulating Factor 1 Etoposide 1 Busulfan 1 Bone Marrow Transplantation 1 Aspirin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Multiple Myeloma × Lenograstim × Clear all

NCT01085058 2010-03-11

CU01

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 2/3 Completed

LymphoidPlasma cell

Hodgkin Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡